Galapagos

Galapagos NV plans to split into two entities to enhance shareholder value: SpinCo, focusing on innovative medicines, and the core company, emphasizing cell therapy in oncology. SpinCo will have $2.53 billion, target key therapeutic areas, and list on Euronext. The split, requiring shareholder approval, aims for completion by mid-2025, involving job cuts and operational streamlining.

Galapagos NV splits into two, focusing on oncology and transactions. Sana, Jasper, and Viking report early data and study starts. Pharma faces a patent cliff, prompting M&A. FDA's Califf expresses concerns over Trump's impact. Tenvie Therapeutics launches with $200M for neuroscience. Medicare may negotiate lower Ozempic prices. East Asians are underrepresented in biopharma leadership.

Galapagos, a biotech firm, plans to split into two companies and cut 300 jobs to unlock shareholder value. A new entity will focus on innovative medicines via acquisitions, while the existing company will concentrate on oncology cell therapy, discontinuing its small molecules division. The reorganization affects 40% of its European workforce, with significant cuts in France and potential site closures. Headquarters remain in Mechelen.

The Inflammatory Myositis market is set to grow significantly by 2034, driven by increasing disease prevalence and new therapies. Key companies include Merck KGaA, Pfizer, and others, with treatments like Brepocitinib and PF-06823859 expected to revolutionize the market. The US led the market in 2023, with a projected CAGR of 11.7% across major markets.

Phase 1/2 ATALANTA-1 study data show high antitumor activity and safety in R/R NHL patients treated with fresh, fit, stem-like early memory CD19 CAR T-cells, with a median vein-to-vein time of seven days, highlighting the potential of Galapagos' decentralized cell therapy manufacturing platform.

The idiopathic pulmonary fibrosis market is projected to grow from $3.89 billion in 2023 to $5.24 billion in 2028 at a CAGR of 6.2%, driven by factors like an aging population, limited treatment options, and advancements in diagnostic techniques. Key trends include product innovation and the rise of targeted therapies.

DelveInsight's report on Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034 details the market size, emerging therapies, and key companies like Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma, Gilead Sciences, Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others. The market size in 7MM was ~USD 9,000 million in 2023, expected to increase by 2034, with key therapies like ENTYVIO, STELARA, VELSIPITY, Zeposia, LY-3074828, RHB-104, and others expected to launch. Positive results for mirikizumab and TREMFYA were reported in 2024, and Dong-A-ST's Imuldosa received FDA approval as a biosimilar to Stelara.

Adaptimmune's TCR-T cell therapy Lete-cel achieved a 42% response rate in NY-ESO-1-positive advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma patients. The company plans to submit a second marketing authorisation application to the FDA by 2025. Adaptimmune received the first accelerated FDA approval for afami-cel, its TCR-T therapy against solid tumours, following support from Galapagos NV.

Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.

Deutsche Bank reduced its price target on Galapagos NV to €28 from €30, maintaining a Hold rating due to the absence of immediate catalysts and clinical development risks. The focus is on data updates from ASH 2024 and the buildup to 2025's catalysts, with no significant stock movement expected in the near term. Galapagos reported solid Q3 results, including a strong cash position and advancements in oncology and immunology programs, but remains unprofitable with declining revenue.